Valion Bio, Inc. - Common Stock, par value $0.0001 per share (TIVC)

CUSIP: 888705308

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
3,106,323
Total 13F shares
63,588
Share change
+38,915
Total reported value
$56,326
Price per share
$0.89
Number of holders
4
Value change
+$31,649
Number of buys
2
Number of sells
2

Quarterly Holders Quick Answers

What is CUSIP 888705308?
CUSIP 888705308 identifies TIVC - Valion Bio, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of TIVC - Valion Bio, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
3i, LP
13D/G
9.9%
307,526
$310,601 +$31,652 31 Mar 2026
Jennifer Ernst
3/4/5
Chief Executive Officer, Director
mixed-class rows
132,397
mixed-class rows
$61,132 18 Dec 2025
Marex Group plc
13F
Company
1.3%
40,942
$59,366 31 Dec 2025
13F
UBS Group AG
13F
Company
0.63%
19,659
$28,506 31 Dec 2025
13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP
13F
Company
0.47%
14,639
$21,227 31 Dec 2025
13F
Michael K. Handley
3/4/5
Chief Operating Officer
mixed-class rows
80,295
mixed-class rows
$11,118 18 Feb 2026
CITIGROUP INC
13F
Company
0.16%
4,998
$7,247 31 Dec 2025
13F
Tower Research Capital LLC (TRC)
13F
Company
0.05%
1,648
$2,390 31 Dec 2025
13F
Lisa G. Wolf
3/4/5
Chief Financial Officer
mixed-class rows
81,169
mixed-class rows
$399 18 Mar 2026
SBI Securities Co., Ltd.
13F
Company
0%
16
$23 31 Dec 2025
13F
BANK OF AMERICA CORP /DE/
13F
Company
0%
13
$19 31 Dec 2025
13F
John Claude
3/4/5
10%+ Owner
class O/S missing
1,196,000
10 Nov 2021
Blake Gurfein
3/4/5
Chief Scientific Officer
mixed-class rows
235,000
mixed-class rows
18 Dec 2024
Veronica Cai
3/4/5
Chief Financial Officer
class O/S missing
117,880
01 Apr 2022
Briana Benz
3/4/5
Chief Financial Officer
class O/S missing
112,500
10 Nov 2021
Ryan Sabia
3/4/5
Chief Operating Officer
class O/S missing
100,000
08 May 2023
Dean Zikria
3/4/5
Director
mixed-class rows
10,500
mixed-class rows
06 Aug 2025
Kimberly Ann Bambach
3/4/5
Interim CFO
class O/S missing
7,500
01 Oct 2024
Karen Drexler
3/4/5
Director
class O/S missing
3,000
30 Sep 2024

Institutional Holders of Valion Bio, Inc. - Common Stock, par value $0.0001 per share (TIVC) as of Q1 2026

As of 31 Mar 2026, Valion Bio, Inc. - Common Stock, par value $0.0001 per share (TIVC) was held by 4 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 63,588 shares. The largest 4 holders included Sanctuary Advisors, LLC, UBS Group AG, SBI Securities Co., Ltd., and Caitong International Asset Management Co., Ltd. This page lists 4 institutional shareholders reporting positions in this security for the Q1 2026 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders
7
Q1 2026 holders
4
Holder diff
-3
Investor Q4 2025 Shares Q1 2026 Shares Share Diff Share Chg % Q4 2025 Value $ Q1 2026 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .